PAID ADVERTISEMENT JUNE 2026 | HEALTHINSIGHT.CA
@MediaplanetCA
A SPECIAL INTEREST SECTION BY MEDIAPLANET
Life Sciences From Seeds to Salmon, Securing Canada's Sovereignty
A
t a moment when Canada is rethinking its supply chains, its food security, and its relationship with the world, the answers to some of our most pressing national questions are already being developed — in one of our smallest provinces. New Brunswick's research strengths are nationally strategic. In Edmundston, the Northern Hardwoods Research Institute (NHRI) is making an invisible forest resource visible, using AI, LiDAR, and satellite imagery to unlock the emerging bioeconomy. In Grand Manan, we built the world's first wild Atlantic salmon marine conservation farm. Atlantic salmon is a keystone species and a cornerstone of Indigenous and coastal life in New Brunswick. In Fredericton, Canada's only national tree seed bank preserves the genetic diversity of 250+ species against climate change — remarkable enough to earn a spot making Canadian forest history aboard NASA's Artemis II. And in Moncton, Chinova Bioworks is replacing synthetic preserva-
tives with mushroom-derived technology already embedded in global food supply chains. These aren't startup stories. They're proof that New Brunswick's research ecosystem is already delivering for Canada, in the exact sectors that define our long-term sovereignty: food, oceans, and forests innovation. New Brunswick is ready to contribute more to Canada's national priorities. It is time for federal research and innovation systems to pivot to reflect our growing potential. Canada's sovereignty doesn't live in its defence budget alone. It lives in its seeds, its salmon, its trees, and its soil — and right now, research in New Brunswick is doing its part to protect them.
WRITTEN BY
Candice Ashley Pollack CEO, ResearchNB
Learn more at researchnb.ca/hilltimes. This article was sponsored by ResearchNB.
Please recycle
Canada’s Health Future Starts with Homegrown Innovation Marjorie Michel discusses strengthening Canada’s life sciences sector through collaboration, clinical trial modernization, and innovation to improve patient care and healthcare resilience.
Read the full interview with Majorie Michel at healthinsight.ca.
How is Canada strengthening collaboration across the life sciences ecosystem to improve health outcomes and system resilience?
“Canada’s life sciences ecosystem is what anchors our health system, and propels the innovations and technologies that can help protect the health of Canadians, grow our nation’s economic prosperity, and maintain our overall health sovereignty. Our new government is focused on initiatives that strengthen collaboration within the life science ecosystem, including academia, industry and healthcare institutions, in order to turn Canadian research discoveries into real-world therapies, medical technologies, and commercial products. Together with the Hon. Mélanie Joly, my counterpart responsible for industry, I recently announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a first of its kind effort involving senior leaders across the sector to explore innovative, made-in-Canada solutions to support reliable and sustainable access to pharmaceuticals in Canada, and maintain our nation’s industrial competitiveness.”
How Dermatological Innovation Is Improving Patient Outcomes Continued innovation by companies like Galderma Canada is resulting in new treatments for Canadians living with inflammatory skin conditions.
A
topic dermatitis (AD) and prurigo nodularis (PN) are chronic inflammatory skin conditions that can involve a substantial, and sometimes not immediately visible, burden. Both AD and PN are characterized by skin lesions and intense persistent itch, which can disrupt sleep, concentration, and overall well-being, and may affect daily functioning at school or in the workplace. People living with these conditions may experience sleep disturbances and social challenges and can experience impacts on their mental well-being. Atopic dermatitis (AD) and prurigo nodularis (PN) often cause invisible suffering, with symptoms that negatively impact people both physically and mentally. The relentless nature of AD and PN symptoms can take a significant physical and emotional toll — so much so that 87 per cent of patients said that being itch-free is their primary treatment goal.
Advancing research, innovation, and access Some people living with PN suffer from itch for over a decade, highlighting the
need for continued research and innovation to advance treatment options for people living with chronic inflammatory skin diseases like AD and PN. The need to ensure that all Canadians have equitable access to those treatments is equally critical.
These efforts reflect continued work toward addressing unmet patient needs and supporting the understanding of the burden associated with these conditions. By getting to the root cause of the itch, this approach has the potential to help alleviate the physical and
psychosocial burden of these conditions.
Supporting patient care Galderma’s 45-year commitment to advancing dermatology care continues to drive innovation in the field. Building on its experience in dermatolog y, Galderma supports ongoing research and the development of approaches to help improve the management of inflammatory skin conditions in Canada,” says Sophie Élise Michaud, Head of Medical Affairs at Galderma Canada. “These efforts reflect continued work toward addressing unmet patient needs and supporting the understanding of the burden associated with these conditions.” Advances in this area rely on continued investment in research, along with a commitment to supporting patient care. Through its ongoing activities in dermatology, Galderma contributes to efforts aimed at improving the management of inflammatory skin conditions for Canadians.
Sophie Élise Michaud Head of Medical Affairs, Galderma Canada
Learn more about the impact of atopic dermatitis and inflammatory skin conditions, the importance of innovation in dermatology care, and the need to improve access to new treatment options for Canadians at galderma.ca. This article was sponsored by Galderma.
Written by Tania Amardeil
Publisher: Arlene Asika Business Development Manager: Maya Mezerhane Country Manager: Samantha Taylor Content & Client Success Manager: Nicole Kansakar Creative Director: Kylie Armishaw Digital Traffic Manager: Vansh Chandwaney All images are from Getty Images unless otherwise credited. This section was created by Mediaplanet and did not involve The Hill Times or its editorial departments. Send all inquiries to ca.editorial@mediaplanet.com.